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OBJECTIVE: To describe demographic features, disease manifestations and therapy in patients with giant cell
arteritis from referral centers in Brazil.
METHODS: A retrospective cohort study was performed on 45 giant cell arteritis patients from three university
hospitals in Brazil. Diagnoses were based on the American College of Rheumatology classification criteria for
giant cell arteritis or temporal artery biopsy findings.
RESULTS: Most patients were Caucasian, and females were slightly more predominant. The frequencies of
disease manifestations were as follows: temporal headache in 82.2%, neuro-ophthalmologic manifestations in
68.9%, jaw claudication in 48.9%, systemic symptoms in 44.4%, polymyalgia rheumatica in 35.6% and extra-
cranial vessel involvement in 17.8% of cases. Aortic aneurysms were observed in 6.6% of patients. A comparison
between patients with biopsy-proven giant cell arteritis and those without temporal artery biopsies did not
yield significant differences in disease manifestations. All patients were treated with oral prednisone, and
intravenous methylprednisolone was administered to nearly half of the patients. Methotrexate was the most
commonly used immunosuppressive agent, and low-dose aspirin was prescribed to the majority of patients.
Relapses occurred in 28.9% of patients, and aspirin had a protective effect against relapses. Females had higher
prevalences of polymyalgia rheumatica, systemic manifestations and jaw claudication, while permanent visual
loss was more prevalent in men.
CONCLUSIONS: Most of the clinical features of Brazilian giant cell arteritis patients were similar to those found
in other studies, except for the high prevalence of neuro-ophthalmic manifestations and permanent blindness
in the Brazilian patients. Aspirin had a protective effect on relapses.
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& INTRODUCTION
Giant cell arteritis (GCA) is a systemic chronic vasculitis of
large- and medium-sized vessels that mainly affects the cranial
branches of arteries originating from the aortic arch in
individuals who are more than 50 years of age (1,2). The
highest annual incidence rates of GCA are found in
Scandinavian countries and the northern United States, where
there are many people of Scandinavian descent; the GCA
incidence rates are lower in southern European countries, such
as in Italy and Spain. The lowest incidence rates have been
reported in Japan, Turkey and Israel and among native
Alaskans (2-5). GCA case series have been published from
different countries (e.g., Saudi Arabia, Mexico, Tunisia and
India) and population groups (e.g., African American, Asian
and Hispanic patients from the United States) (3-6).
To our knowledge, the only data on the epidemiology of
GCA in the Brazilian population are two case reports and a
small study evaluating anterior ischemic optic neuropathy
(AION) in GCA patients (7-9). Therefore, this study aimed
to describe the demographic features, disease manifesta-
tions, therapy and outcomes of Brazilian patients with GCA.
& MATERIALS AND METHODS
Study design and protocol
We performed a retrospective cohort study to evaluate
Brazilian patients who fulfilled the American College of
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Rheumatology (ACR) Criteria for GCA (10) and who were
under regular follow-up in three tertiary university hospi-
tals (Universidade Federal de Sa˜o Paulo, Universidade de
Sa˜o Paulo and Universidade do Estado do Rio de Janeiro).
The study was approved by the institutional ethics
committees, and data were collected between 2009 and 2010.
Patients’ medical records were reviewed to collect data
according to a standardized protocol. Demographic features
included age at diagnosis and at study date, gender, ethnicity
and information on ancestry. We recorded information about
systemic symptoms, temporal and occipital headache, jaw
claudication, neuro-ophthalmic manifestations of GCA,
partial or complete vision loss secondary to GCA neuro-
ophthalmic manifestations, neurological manifestations, such
as transient ischemic attacks, ischemic stroke and peripheral
neuropathy, symptoms of polymyalgia rheumatica (PMR),
involvement of large- and/or middle-sized vessels and
erythrocyte sedimentation rate (ESR) at disease onset.
Neuro-ophthalmic manifestations of GCA were defined as
amaurosis fugax, diplopia, AION or posterior ischemic optic
neuritis (PION) and central retinal artery occlusion.
A positive temporal artery biopsy was considered when
vasculitic findings, such as inflammatory infiltrate on an
arterial wall with or without granuloma and multinucleated
giant cells, were described upon pathological examination
of temporal artery specimens. The investigation of extra-
cranial artery involvement was performed by computed
tomography angiography or magnetic resonance angiogra-
phy when patients presented vascular signs and symptoms,
such as limb claudication, vascular bruits or a decrease in
arterial pulses, or when imaging studies performed for
other purposes displayed arterial abnormalities. When the
aorta and/or its main branches were affected by aneurysms,
stenosis or arterial occlusions, this was regarded as extra-
cranial artery involvement. Comorbidities and/or compli-
cations of secondary glucocorticoid therapy presented by
GCA patients were recorded. Disease relapse was consid-
ered when the patient presented typical manifestations of
GCA associated with an increased ESR (. 50 mm/1st hour)
after excluding secondary causes, such as infections. Deaths
that occurred during the follow-up period were recorded.
The GCA disease course was classified (according to the
presence or absence of relapses) as monophasic or relapse-
remitting.
We evaluated medical therapies, including prednisone
use, pulse therapy with methylprednisolone, methotrexate
or another immunosuppressive agent, antiplatelet therapy
and statins. Patients with active GCA and visual symptoms
were initially treated with high-dose prednisone (1 mg/kg/
day) with intravenous pulse methylprednisolone (1 g/day
for three days), while patients presenting uncomplicated
forms of GCA were initially treated with prednisone
(40 mg/day). Prednisone tapering began after the resolution
of active GCA symptoms and was performed at the
physician’s discretion. Methotrexate was added after the
first relapse as a steroid-sparing agent and to prevent more
disease relapses. If patients could not tolerate methotrexate,
it was replaced by another immunosuppressive agent, such
as azathioprine or oral cyclophosphamide.
Statistical analysis
SPSS software (version 15.0) was used to carry out the
statistical analyses. Categorical data are presented as total
numbers and percentages, and numerical data are presented
as the means, medians, standard deviations, ranges or as
95% confidence intervals (CIs). Comparisons between
groups were performed using a chi-square test or Fisher’s
exact test for categorical data and Student’s t-test or Mann-
Whitney U-test for continuous variables. Univariate and
multivariate logistic regression models analyzed associa-
tions with relapses, and results are expressed as odds ratios
(ORs) and 95% CIs.
& RESULTS
Demographic features and GCA manifestations
The median ages of the 45 GCA patients at the time of
study and at disease onset were 78.0 (95% CI: 73.2–78.4) and
73.0 (95% CI: 68.7–73.7) years, respectively. In 23 (51.1%)
patients, diagnoses of GCA were made between 70 and 79
years of age, and no patients had onset of disease
manifestations before age 50 or after age 90. The mean
follow-up period was 54.9¡41.9 months. The female-to-
male ratio was 1.8:1.0, and most GCA patients were
Caucasians (86.7%), while 13.3% were mestizos. Among
Caucasian GCA patients, 69.2% were of Portuguese, 25.6%
of Italian and 5.2% of Spanish descent.
Table 1 describes the prevalence of GCA manifestations in
this sample of Brazilian patients. Although all patients
fulfilled the ACR criteria for GCA, a temporal artery biopsy
was performed on only 18 (40.0%) patients, and it displayed
features of vasculitis in 16 of those (88.8%) cases. No
significant differences in demographic features, disease
manifestations or ESR were found between patients with
biopsy-proven GCA and those classified as GCA according
to the ACR criteria (Table 2). All patients with neuro-
ophthalmic manifestations developed AION, and it was
preceded by amaurosis fugax in 11 cases. No patients
developed diplopia, PION or central retinal artery occlu-
sions. In all but one patient with permanent visual loss,
amaurosis developed at disease onset in patients presenting
neuro-ophthalmic manifestations who did not show
improvement in visual acuity after commencing glucocorti-
coids. Only one patient developed permanent visual loss
(unilateral amaurosis) during a relapse. Among patients
with extra-cranial artery involvement, aortic aneurysms
were found in three patients (6.6%), the thoracic aorta was
involved in two patients (4.4%), and the abdominal aorta
Table 1 - Manifestations of giant cell arteritis among
Brazilian patients.
Manifestation Frequency
Systemic manifestations, n (%) 20 (44.4)
Fever, n (%) 14 (31.1)
Anorexia, n (%) 13 (28.9)
Weight loss, n (%) 17 (37.8)
Temporal headache, n (%) 37 (82.2)
Occipital headache, n (%) 6 (13.3)
Jaw claudication, n (%) 22 (48.9)
Anterior ischemic optic neuritis, n (%) 31 (68.9)
Amaurosis fugax, n (%) 11 (24.4)
Permanent visual loss, n (%) 16 (35.5)
Unilateral visual loss, n (%) 10 (22.2)
Bilateral visual loss, n (%) 6 (13.3)
Polymyalgia rheumatica, n (%) 16 (35.6)
Extracranial vessel involvement, n (%) 8 (17.8)
Neurologic manifestations, n (%) 3 (6.7)
n - number of patients.
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was involved in one patient (2.2%). The dissection of the
thoracic aorta was observed in only one patient (2.2%) with
an aortic aneurysm. Stenosis of extra-cranial arteries was
found in five (11.1%) patients with GCA. Subclavian arteries
were involved in four cases (8.8%), common carotid arteries
were involved in two (4.4%), and the common iliac arteries
and superior mesenteric artery were involved in one patient
each (2.2%). No patients developed cervical artery stenosis.
Peripheral neuropathy was the only neurologic manifesta-
tion observed, and no patients developed stroke during the
follow-up period. The mean ESR value at disease onset was
78.4¡33.4 mm/1st hour.
Therapy
All patients were treated with oral corticosteroids at
disease onset and during any relapses; intravenous methyl-
prednisolone was administered to 23 (51.1%) patients. Oral
weekly methotrexate was prescribed to 21 (46.7%) patients at
a median dose of 15 mg (95% CI: 14.8–18.5). An alternative
immunosuppressive agent was prescribed to four GCA
patients (8.8%); two patients took oral cyclophosphamide,
and two took azathioprine. Aspirin was prescribed to 32
(71.1%) and statins to 16 (35.6%) patients.
Relapses
Most GCA patients had a monophasic disease course, and
relapses were observed in 13 (28.9%) patients. The median
number of relapses was 1.0 (95% CI: 0.99–1.93). PMR was
the most common reactivation form (occurring in six
relapses). AION occurred in five relapses, new onset of
temporal headache occurred in three, extra-cranial vasculitis
occurred in two, and polyarthritis occurred in one. Jaw
claudication, PMR and the involvement of large vessels
were the GCA manifestations most commonly found during
disease course among relapsing patients compared with
patients with monophasic disease. Patients with monopha-
sic disease used aspirin more frequently than relapsing
patients, and no significant relapse differences were found
in GCA patients treated with methylprednisolone intrave-
nous pulse, methotrexate or statins (Table 3).
Univariate analysis showed that aspirin had a protective
effect against relapses (OR 0.19; 95% CI: 0.04–0.80;
p= 0.024). A higher risk for relapse was found in GCA
patients who presented PMR (OR 8.03; 95% CI: 1.89–34.10;
p= 0.005), jaw claudication (OR 10.5; 95% CI: 1.96–55.99;
p= 0.006) and the involvement of extra-cranial arteries (OR
6.04; 95% CI: 1.18–30.87; p= 0.031). After adjusting for age,
gender and ethnicity in a multivariate model, the beneficial
effects of aspirin use to prevent relapses (OR 0.02; 95% CI:
0.001–0.60; p= 0.023), as well as the higher risk for relapses
associated with jaw claudication (OR 21.86; 95% CI: 1.32–
360.28; p= 0.031) and the involvement of extra-cranial
arteries (OR 45.91; 95% CI: 1.40–1503.54; p= 0.032), re-
mained significant.
Outcomes
During follow-up, 41 (91.1%) GCA patients developed at
least one complication related to long-term corticosteroid
use, including systemic hypertension (66.7%), dyslipidemia
(37.8%), osteoporosis (37.8%), diabetes (33.3%), cataracts
(20.0%) or glaucoma (8.9%). Coronary heart disease was
observed in only two patients (4.4%) during the follow-up
period. Four GCA patients (8.9%) developed cancer during
the study period; lymphoma was diagnosed in two patients,
and skin basal cell carcinoma and breast cancer were
diagnosed in one patient each. Four GCA patients (8.9%)
died during the study, including three from neoplasia (two
with lymphoma and one with breast cancer) and one with
sepsis due to severe pneumonia.
Comparisons between genders
Female GCA patients had a higher prevalence of PMR,
systemic manifestations and jaw claudication than male
patients. Moreover, they developed more osteoporosis and
dyslipidemia during the course of the disease as complica-
tions due to chronic steroid therapy. Permanent visual loss
was significantly more prevalent in men with GCA than
women (Table 4).
& DISCUSSION
To the best of our knowledge, this is the first study
addressing the features of Brazilian GCA patients. Jaw
claudication, PMR and extra-cranial vessel involvement
were more commonly found in patients with relapsing
disease. Furthermore, female patients had a higher pre-
valence of PMR, systemic manifestations and jaw claudica-
tion than men, while the latter developed permanent visual
loss more frequently. Finally, antiplatelet therapy was
associated with a lower relapse rate. The purpose of this
study was to describe GCA features in a country where
GCA is uncommon.
Table 2 - Comparison between patients with biopsy-proven GCA and those classified according the ACR criteria for GCA.
Variables Biopsy-proven GCA (N=16) GCA based on ACR criteria (N =29) p-value
Median age at study, years 80.5 (56-87) 78.0 (58-86) 0.141
Females, n (%) 12 (75.0) 17 (58.6) 0.221
Caucasians, n (%) 14 (87.5) 25 (86.2) 0.642
Temporal headache, n (%) 13 (81.3) 24 (82.8) 0.600
Occipital headache, n (%) 0 (0.0) 6 (20.7) 0.058
Jaw claudication, n (%) 7 (43.8) 15 (51.7) 0.608
Polymyalgia rheumatic, n (%) 3 (18.8) 13 (44.8) 0.075
Systemic manifestations, n (%) 7 (43.8) 13 (44.8) 0.944
Neuro-ophthalmic manifestations, n (%) 13 (81.3) 18 (62.1) 0.160
Extracranial vessel involvement, n (%) 3 (18.8) 5 (17.2) 0.600
Neurological manifestations, n (%) 2 (12.5) 1 (3.4) 0.285
Mean ESR at diagnosis, mm/hour 90.1¡41.7 71.3¡25.7 0.075
Numerical data are presented as the medians and ranges or as the means ¡ standard deviations; ACR – American College of Rheumatology; ESR –
erythrocyte sedimentation rate; GCA – giant cell arteritis; n – number of patients.
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The median age of disease onset among Brazilian GCA
patients was 73.0 years, which falls within the previously
described peak of incidence between 70 and 80 years of age
(4,11). The age of disease onset of approximately half of our
patients was clustered between 70 and 79 years. However,
we found no increase in GCA incidence rate in patients
between 80 and 89 years of age, and no cases of GCA were
diagnosed after the age of 90 years. This differs from the
literature, in which the risk of developing GCA increases
with advancing age and the incidence of GCA is 20-fold
higher among individuals older than 90 years than in those
between 50 and 60 years (12).
Similarly to other studies, Brazilian GCA patients were
predominantly female (1,2). The reason for this is not
completely understood; sex-based hormonal differences
could be a possible explanation because androgens seem
to play a protective role against autoimmunity and men are
exposed to higher androgen levels than women throughout
their lives. Due to the post-menopausal onset of GCA,
estrogens are less likely to be involved in the pathogenesis
(13,14). No significant differences in GCA manifestations
between genders have been found in large series evaluating
patients with GCA; only an increased prevalence of head-
ache in women was observed in the study performed by
Machado et al. (15). However, the higher prevalence of PMR
and systemic manifestations among female patients and the
higher prevalence of permanent visual loss among the men
in our study are in accordance with the results observed in
studies that specifically addressed sex differences in GCA
(13,16,17).
The prevalences of most GCA manifestations in Brazilian
patients are similar to those described by other studies; the
Table 3 - Comparison between monophasic and relapsing patients with giant cell arteritis.
Variables Relapsing patients (n = 13) Non-relapsing patients (n = 32) p-value
Median age at onset, years 70.0 (54-80) 75.5 (55-82) 0.065
Females, n (%) 11 (84.6) 18 (56.3) 0.072
Non-Caucasians, n (%) 3 (21.1) 3 (9.4) 0.220
Polymyalgia rheumatica, n (%) 9 (69.2) 7 (21.9) 0.003*
Systemic manifestations, n (%) 7 (53.8) 13 (40.6) 0.419
Temporal headache, n (%) 11 (84.6) 26 (81.3) 0.789
Occipital headache, n (%) 2 (15.4) 4 (12.5) 0.796
Jaw claudication, n (%) 11 (84.6) 11 (34.4) 0.002*
Neuro-ophthalmic manifestations, n (%) 7 (53.8) 24 (75.0) 0.165
Permanent visual loss, n (%) 3 (23.1) 13 (40.6) 0.265
Extra-cranial vessel involvement, n (%) 5 (38.5) 3 (9.4) 0.021
Mean ESR at diagnosis, mm/hour 69.3¡44.6 82.7¡27.2 0.346
Methotrexate use, n (%) 8 (61.5) 13 (40.6) 0.202
Intravenous pulse with MP, n (%) 5 (38.5) 18 (56.3) 0.279
Statins use, n (%) 6 (46.2) 10 (31.3) 0.344
Aspirin use, n (%) 6 (46.2) 26 (81.3) 0.019
Deaths, n (%) 2 (15.4) 2 (6.3) 0.329
Numerical data are presented as the medians and ranges or as the means ¡ standard deviations; ESR - erythrocyte sedimentation rate; n - number of
patients; MP – methylprednisolone.
Table 4 - Comparison between males and females with giant cell arteritis.
Variables Females (n = 29) Males (n= 16) p-value
Mean age at onset, years 70.3¡6.5 72.9¡9.1 0.323
Non-Caucasians, n (%) 6 (20.7) 0 (0.0) 0.051
Polymyalgia rheumatica, n (%) 14 (48.3) 2 (12.5) 0.016*
Systemic manifestations, n (%) 17 (58.6) 3 (18.8) 0.010*
Temporal headache, n (%) 26 (89.7) 11 (68.8) 0.079
Occipital headache, n (%) 4 (13.8) 2 (12.5) 0.903
Jaw claudication, n (%) 20 (69.0) 2 (12.5) ,0.001
Neuro-ophthalmic manifestations, n (%) 19 (65.5) 12 (75.0) 0.511
Permanent visual loss, n (%) 6 (20.7) 10 (62.5) 0.005*
Extra-cranial vessel involvement, n (%) 5 (17.2) 3 (18.8) 0.899
Mean ESR at diagnosis, mm/hour 80.3¡34.4 74.2¡31.8 0.579
Complications due to steroid therapy, n (%) 28 (96.6) 13 (81.3) 0.084
Systemic hypertension, n (%) 22 (75.9) 8 (50.0) 0.078
Diabetes, n (%) 12 (41.4) 3 (18.8) 0.123
Dyslipidemia, n (%) 15 (51.7) 2 (12.5) 0.009
Osteoporosis, n (%) 15 (51.7) 2 (12.5) 0.009
Cataracts, n (%) 4 (13.8) 5 (31.3) 0.161
Glaucoma, n (%) 2 (6.9) 2 (12.5) 0.527
Coronary heart disease, n (%) 2 (6.9) 0 (0.0) 0.283
Cancer, n (%) 3 (10.3) 1 (6.3) 0.644
Deaths, n (%) 3 (10.3) 1 (6.3) 0.644
Numerical data are presented as the medians and ranges or as the means ¡ standard deviations; ESR - erythrocyte sedimentation rate; n - number of
patients.
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only exception is the lower prevalence of systemic manifesta-
tions, such as fever, anorexia and weight loss, in Brazilian
patients (1-3,6,15). Due to the retrospective nature of this
study, systemic manifestations may have been undervalued
and not indicated in the medical records. The high prevalence
of neuro-ophthalmic manifestations in this study may be due
to referral bias because most GCA patients were referred by
ophthalmologists (i.e., all 31 patients with neuro-ophthalmic
manifestations). Thus, the high rate of permanent visual loss
may reflect the higher prevalence of visual symptoms, in
addition to reflecting the delay in recognition of disease
features and the low threshold for the diagnosis of GCA due
to its rarity in Brazil. Salvarani et al. (18) showed that most
cases of permanent visual loss develop prior to the start of
corticosteroid therapy. AION was the leading neuro-ophthal-
mic manifestation in our patients, and it has been reported in
approximately 90% of patients with visual symptoms due to
GCA (18,19). Amaurosis fugax is recognized as a risk factor
for the cranial ischemic complications of GCA (20), and it
preceded AION in one-third of our cases.
The prevalence of aortic aneurysms in our patients was
lower than the 9.5–18.0% previously described (21,22).
Despite the low prevalence of aortic aneurysms in this
study, one patient developed an aneurysm dissection in the
thoracic aorta, and this life-threatening complication reaf-
firms the importance of evaluating GCA patients for large
vessel involvement. The prevalence of arterial stenosis in
our study is similar to the 13–14% previously described, and
it involved mainly subclavian and common carotid arteries
(22,23).
In this study, corticosteroids were the most prescribed
therapy for active GCA. Although a small trial that included
biopsy-proven GCA patients found that intravenous
methylprednisolone led to a higher rate of sustained
remission, a lower daily dose of prednisone and lower
cumulative dose of glucocorticoid, in this study, it was
reserved mostly for patients with neuro-ophthalmic mani-
festations (24). Methotrexate was prescribed to our patients
after the first relapse based on a meta-analysis that showed
the benefit of methotrexate in preventing relapses and
reducing exposure to corticosteroids (25).
The frequency of disease relapses in our study was
slightly lower than the 30–50% described by other studies
(26-29). Although PMR and temporal headache are common
features observed in relapsing GCA (26), we found an
unexpectedly high frequency of AION among relapsing
patients. We also found higher prevalences of PMR, jaw
claudication and extra-cranial vessel involvement as GCA
manifestations during the course of the disease in relapsing
patients. However, in a study that specifically addressed
relapses in patients with GCA, no significant differences
were found in the disease manifestations of relapsing and
non-relapsing patients (26).
Two retrospective cohort studies (30,31) found that
antiplatelet therapy with low-dose aspirin reduces cranial
ischemic complications of GCA, including visual loss and
cerebrovascular accidents. Most of our patients were treated
with low-dose aspirin, and we observed a protective effect
of aspirin on disease relapses. We speculate that the
prevention of cranial complications may have accounted
for the lower rate of relapses in patients treated with aspirin.
Narva´ez et al. (32) did not find any effect of aspirin on either
the prevention of cranial ischemic complications or GCA
relapse rates.
Limitations of this study include its retrospective design,
the relatively small number of patients and the fact that it
was based on referral centers. Most limitations may be
explained by the rarity of GCA in Brazil. In this setting,
essentially all recognized patients with GCA are referred to
tertiary centers for follow-up and management. Referral
delays and previous treatment with high-dose corticoster-
oids are some reasons for the relatively low frequency of
temporal artery biopsy (40%) in GCA patients observed in
this study. Another limitation of this study is the under-
estimation of extra-cranial arterial involvement in GCA, as
its screening in our patients relied only on signs and
symptoms of vascular manifestations and finding vascular
abnormalities by chance on imaging studies performed for
other purposes. It is now well known that extra-vascular
involvement can occur asymptomatically, even at the time
of GCA diagnosis (33).
In conclusion, GCA in Brazil is mostly found among
female Caucasians, and the majority of clinical features are
similar to those found in other studies, except for the low
frequency of systemic symptoms and high prevalence of
neuro-ophthalmic manifestations, including permanent
blindness. A significant protective effect of aspirin against
disease relapses was observed.
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